In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Epimmune grants Amgen non-exclusive license to PADRE(R) technology
Epimmune grants Anosys license to cancer epitopes
Epimmune licenses PADRE technology to Elan
Epimmune reports promising results on vaccine immune stimulant
Epimmune and Beckman Coulter sign license agreement
Epimmune and Rhein Biotech sign research agreement
Immuno-Designed Molecules exercises license option
Epimmune announces milestone in Genencor collaboration